Tech Company Financing Transactions

Attovia Therapeutics Funding Round

Goldman Sachs, Cormorant Asset Management and EcoR1 Capital Management participated in a $105 million Series B funding round for Attovia Therapeutics. The funding round was announced by the company on 5/9/2024.

Transaction Overview

Announced On
5/9/2024
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance the Company's lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Company's immunology and inflammation pipeline, and to further develop the ATTOBODY� platform.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
47071 Bayside Parkway
Fermont, CA 94538
USA
Phone
Undisclosed
Website
Email Address
Overview
Attovia is focused on creating a pipeline of biotherapeutics in immune-mediated disease and oncology. The company leverages AttobodyTM, Alamar Biosciences' novel biparatopic nanobody platform, to generate small format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration. Attovia's lead program is an Attobody to treat immune disease. The company is currently progressing multiple programs and plans to initiate additional discovery projects.
Profile
Attovia Therapeutics LinkedIn Company Profile
Social Media
Attovia Therapeutics Company Twitter Account
Company News
Attovia Therapeutics News
Facebook
Attovia Therapeutics on Facebook
YouTube
Attovia Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Tao Fu
  Tao Fu LinkedIn Profile  Tao Fu Twitter Account  Tao Fu News  Tao Fu on Facebook
Chief Technical Officer
Hangjun Zhan
  Hangjun Zhan LinkedIn Profile  Hangjun Zhan Twitter Account  Hangjun Zhan News  Hangjun Zhan on Facebook
Co-Founder
Yuling Luo
  Yuling Luo LinkedIn Profile  Yuling Luo Twitter Account  Yuling Luo News  Yuling Luo on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/9/2024: CoverTree venture capital transaction
Next: 5/9/2024: Lagrange Labs venture capital transaction

 

Share this article

 


News on VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary